Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | NCF1 | P14598 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413404 | 0.87 | HTR6 (0.50) | HTR6NCF1CYP3A4CYP2D6 | |
| SCHEMBL1413301 | 0.86 | NCF1 (0.44) | NCF1HPGDSMN1; SMN2KDM4EGAA | |
| SCHEMBL11786609 | 0.74 | HTR6 (0.54) | HTR6NCF1HPGDSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11844003 | 0.73 | HTR6 (0.52) | HTR6NCF1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL424495 | 0.73 | SLC6A2 (0.45) | HTR6HPGDSMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL15024911 | 0.72 | SMN1; SMN2 (0.33) | HPGDSMN1; SMN2KDM4EMAPK1KMT2A | |
| SCHEMBL1077030 | 0.71 | GPR3 (0.33) | HTR6HPGDSMN1; SMN2MAPK1MEN1 | |
| SCHEMBL29830999 | 0.71 | GPR3 (0.33) | HTR6HPGDSMN1; SMN2MAPK1MEN1 | |
| SCHEMBL23536600 | 0.69 | HTR6 (0.51) | HTR6HPGDSMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL4306537 | 0.69 | HTR6 (0.50) | HTR6CYP3A4CYP2D6MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | HTR6 172/4885NCF1 672/4885HPGD 2824/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | HTR6 142/4885NCF1 672/4885HPGD 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.